Osborne Partners Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Osborne Partners Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.7M	Sell	169,027 -1,812	-1%	-$245K	1.49%	19
2026 Q1	$21.8M	Sell	170,839 -10,125	-6%	-$1.26M	1.15%	23
2025 Q4	$22.1M	Sell	180,964 -6,601	-4%	-$757K	1.14%	21
2025 Q3	$18.8M	Buy	187,565 +1,713	+0.9%	+$154K	0.95%	30
2025 Q2	$15.4M	Buy	185,852 +83,572	+82%	+$6.67M	0.82%	37
2025 Q1	$8.29M	Buy	102,280 +3,373	+3%	+$301K	0.48%	74
2024 Q4	$8.91M	Buy	98,907 +4,900	+5%	+$475K	0.52%	71
2024 Q3	$9.29M	Buy	94,007 +1,165	+1%	+$114K	0.53%	67
2024 Q2	$8.61M	Buy	92,842 +3,365	+4%	+$302K	0.52%	68
2024 Q1	$8.49M	Buy	89,477 +1,269	+1%	+$118K	0.52%	71
2023 Q4	$7.88M	Buy	88,208 +3,723	+4%	+$276K	0.52%	68
2023 Q3	$6.17M	Buy	84,485 +1,065	+1%	+$85.1K	0.46%	73
2023 Q2	$6.94M	Buy	83,420 +1,284	+2%	+$107K	0.5%	68
2023 Q1	$6.26M	Buy	82,136 +1,490	+2%	+$124K	0.46%	82
2022 Q4	$6.69M	Sell	80,646 -1,854	-2%	-$150K	0.53%	69
2022 Q3	$6.54M	Buy	82,500 +3,540	+4%	+$298K	0.55%	65
2022 Q2	$5.86M	Buy	78,960 +1,772	+2%	+$133K	0.45%	76
2022 Q1	$6.94M	Buy	+77,188	New	+$7.13M	0.51%	67

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Osborne Partners Capital Management's XBI Position: Q2 2026 in Review

Osborne Partners Capital Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 1.1% in Q2 2026, selling an estimated $245K and leaving 169,027 shares worth $26.7M. The position accounts for 1.49% of the portfolio, ranked #19.

Osborne Partners Capital Management first reported a position in XBI in Q1 2022 and has held it in 18 quarters since. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Osborne Partners Capital Management held 169,027 shares of State Street SPDR S&P Biotech ETF worth $26.7M as of Q2 2026.
Osborne Partners Capital Management sold 1,812 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $245K.
State Street SPDR S&P Biotech ETF made up 1.49% of Osborne Partners Capital Management's portfolio in Q2 2026, its #19 holding.
Osborne Partners Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and has held it in 18 quarters since.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Osborne Partners Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.